BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 9473065)

  • 21. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
    Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
    Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
    Kley N; Whaley J; Seizinger BR
    Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus.
    Sainio M; Jääskeläinen J; Pihlaja H; Carpén O
    Neurology; 2000 Mar; 54(5):1132-8. PubMed ID: 10720287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis.
    Jacoby LB; MacCollin M; Parry DM; Kluwe L; Lynch J; Jones D; Gusella JF
    Neurogenetics; 1999 Apr; 2(2):101-8. PubMed ID: 10369886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.
    Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN
    J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors.
    Kluwe L; Friedrich RE; Hagel C; Lindenau M; Mautner VF
    J Invest Dermatol; 2000 May; 114(5):1017-21. PubMed ID: 10771486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree.
    MacCollin M; Mohney T; Trofatter J; Wertelecki W; Ramesh V; Gusella J
    JAMA; 1993 Nov; 270(19):2316-20. PubMed ID: 8230593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofibromatosis type 2 appears to be a genetically homogeneous disease.
    Narod SA; Parry DM; Parboosingh J; Lenoir GM; Ruttledge M; Fischer G; Eldridge R; Martuza RL; Frontali M; Haines J
    Am J Hum Genet; 1992 Sep; 51(3):486-96. PubMed ID: 1496982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurofibromatosis type 2.
    Uppal S; Coatesworth AP
    Int J Clin Pract; 2003 Oct; 57(8):698-703. PubMed ID: 14627181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.
    Mérel P; Hoang-Xuan K; Sanson M; Moreau-Aubry A; Bijlsma EK; Lazaro C; Moisan JP; Resche F; Nishisho I; Estivill X
    Genes Chromosomes Cancer; 1995 Jul; 13(3):211-6. PubMed ID: 7669741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency and distribution of NF2 mutations in schwannomas.
    Jacoby LB; MacCollin M; Barone R; Ramesh V; Gusella JF
    Genes Chromosomes Cancer; 1996 Sep; 17(1):45-55. PubMed ID: 8889506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.
    Paganini I; Capone GL; Vitte J; Sestini R; Putignano AL; Giovannini M; Papi L
    J Neurooncol; 2018 Mar; 137(1):33-38. PubMed ID: 29230670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level.
    Neff BA; Welling DB; Akhmametyeva E; Chang LS
    Otol Neurotol; 2006 Feb; 27(2):197-208. PubMed ID: 16436990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
    Kley N; Seizinger BR
    Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presymptomatic DNA and MRI diagnosis of neurofibromatosis 2 with mild clinical course in an extended pedigree.
    Sainio M; Strachan T; Blomstedt G; Salonen O; Setälä K; Palotie A; Palo J; Pyykkö I; Peltonen L; Jääskeläinen J
    Neurology; 1995 Jul; 45(7):1314-22. PubMed ID: 7617190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.
    Evans DG; Trueman L; Wallace A; Collins S; Strachan T
    J Med Genet; 1998 Jun; 35(6):450-5. PubMed ID: 9643284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor.
    MacCollin M
    Brain Dev; 1995; 17(4):231-8. PubMed ID: 7503383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
    Nowak A; Dziedzic T; Czernicki T; Kunert P; Morawski K; Niemczyk K; Marchel A
    Neurol Neurochir Pol; 2015; 49(5):295-301. PubMed ID: 26377980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Type 2 neurofibromatosis without acoustic neuroma].
    Mautner VF; Lindenau M; Köppen J; Hazim W; Kluwe L
    Zentralbl Neurochir; 1995; 56(2):83-7. PubMed ID: 7639047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.